Table 1 Clinical characteristics of the study population in the 2016–2018 KURAMA cohort
n = 224 | 2016 | 2017 | 2018 |
|---|---|---|---|
The positivity of anti-cit-OPN antibody, % | 44.2 | 43.3 | 45.5 |
The positive rate of anti-cit-OPN antibody in anti-CCP antibody-positive patients, % | 53.5 | 50.9 | 52.4 |
DAS28-CRP | 2.09 ± 0.81 | 2.10 ± 0.81 | 1.94 ± 0.73 |
DAS28-ESR | 2.64 ± 0.96 | 2.66 ± 0.99 | 2.43 ± 0.97 |
Anti-CCP antibody, U/mL | 266.0 ± 444.7 | 355.6 ± 566.3 | 403.5 ± 772.1 |
The rate of anti-CCP antibody positive, % | 77.8 | 77.7 | 78.0 |
Rheumatoid factor, IU/mL | 119.7 ± 240.4 | 120.6 ± 264.4 | 130.1 ± 296.0 |
The rate of rheumatoid factor positive, % | 77.7 | 80.0 | 78.6 |
CRP, mg/dL | 0.36 ± 0.74 | 0.36 ± 0.64 | 0.38 ± 0.73 |
ESR 1 h, mm/h | 20.6 ± 16.3 | 21.1 ± 16.7 | 20.3 ± 17.6 |
ptVAS, 0–100 mm | 22.3 ± 21.8 | 22.9 ± 21.8 | 23.0 ± 22.6 |
The use of PSL, % | 22.8 | 22.3 | 22.3 |
PSL dose, mg/day | 3.78 ± 4.16 | 3.29 ± 2.10 | 3.31 ± 1.73 |
The use of MTX, % | 75.0 | 74.6 | 73.7 |
MTX dose, mg/week | 7.37 ± 3.13 | 7.50 ± 3.16 | 7.47 ± 3.28 |
The use of biologic DMARDs, % | 50.9 | 52.2 | 54.5 |